Cargando…
Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
GM-CSF promotes myelopoiesis and inflammation, and GM-CSF blockade is being evaluated as a treatment for COVID-19-associated hyperinflammation. Alveolar GM-CSF is, however, required for monocytes to differentiate into alveolar macrophages (AMs) that control alveolar homeostasis. By mapping cross-spe...
Autores principales: | Bosteels, Cedric, Van Damme, Karel F.A., De Leeuw, Elisabeth, Declercq, Jozefien, Maes, Bastiaan, Bosteels, Victor, Hoste, Levi, Naesens, Leslie, Debeuf, Nincy, Deckers, Julie, Cole, Basiel, Pardons, Marion, Weiskopf, Daniela, Sette, Alessandro, Weygaerde, Yannick Vande, Malfait, Thomas, Vandecasteele, Stefaan J., Demedts, Ingel K., Slabbynck, Hans, Allard, Sabine, Depuydt, Pieter, Van Braeckel, Eva, De Clercq, Jozefien, Martens, Liesbet, Dupont, Sam, Seurinck, Ruth, Vandamme, Niels, Haerynck, Filomeen, Roychowdhury, Debasish F., Vandekerckhove, Linos, Guilliams, Martin, Tavernier, Simon J., Lambrecht, Bart N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663750/ https://www.ncbi.nlm.nih.gov/pubmed/36459994 http://dx.doi.org/10.1016/j.xcrm.2022.100833 |
Ejemplares similares
-
GM-CSF in inflammation
por: Hamilton, John A.
Publicado: (2019) -
G-CSF and GM-CSF in clinical trials.
por: Antman, K. H.
Publicado: (1990) -
Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
por: Lazarus, Hillard M., et al.
Publicado: (2023) -
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
por: De Leeuw, Elisabeth, et al.
Publicado: (2022) -
Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19
por: Van Damme, Karel F. A., et al.
Publicado: (2020)